Updated Jul 16, 2026
WILSON TROY EDWARD has filed 1 SEC Form 4 filing across 1 company in the last 90 days — active on both sides. Lifetime open-market purchases: $713K. Lifetime open-market sales: $6.16M. Historical track record: 5/5 stars across 3 tracked purchases.
Troy Edward Wilson is the President and CEO of Kura Oncology, Inc., a biopharmaceutical company focused on precision medicines for cancer treatment. He has also held leadership roles at Avidity Biosciences, Inc., contributing to the development of innovative therapies.
| Role | Director |
|---|---|
| Notability | 30/100 |
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★★★★★ (5/5) |
|---|---|
| Total purchases tracked | 3 |
| Purchases with forward-return data | 3 |
| 30-day win rate | 10000% |
| 90-day win rate | 10000% |
| Avg 5-day return | +1225.31% |
| Avg 30-day return | +3078.86% |
| Avg 90-day return | +5805.47% |
| Best 30-day return | +4233.87% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-16 | PBYI | PUMA BIOTECHNOLOGY, INC. | S — Open-market sale | 10.8K | $7.20 | $78K |
| 2026-06-16 | PBYI | PUMA BIOTECHNOLOGY, INC. | A — Grant or award | 27.0K | $0.00 | |
| 2026-03-25 | KURA | Kura Oncology, Inc. | M — Option exercise | 6.1K | $6.15 | $38K |
| 2026-02-27 | RNAM | Avidity Biosciences, Inc. | D — Derivative transaction | 13.7K | — | |
| 2026-02-27 | RNAM | Avidity Biosciences, Inc. | D — Derivative transaction | 65.1K | — | |
| 2025-11-15 | KURA | Kura Oncology, Inc. | A — Grant or award | 182.5K | $0.00 | |
| 2025-09-27 | KURA | Kura Oncology, Inc. | S — Open-market sale | 36.6K | $8.94 | $327K |
| 2025-09-27 | KURA | Kura Oncology, Inc. | A — Grant or award | 182.5K | $0.00 | |
| 2025-09-08 | KURA | Kura Oncology, Inc. | P — Open-market purchase | 50.0K | $8.20 | $410K |
| 2025-09-05 | RNAM | Avidity Biosciences, Inc. | S — Open-market sale | 15.0K | $50.00 | $750K |
| 2025-09-05 | RNAM | Avidity Biosciences, Inc. | S — Open-market sale | 14.5K | $50.00 | $725K |
| 2025-09-05 | RNAM | Avidity Biosciences, Inc. | M — Option exercise | 14.5K | $12.48 | $181K |
| 2025-08-12 | KURA | Kura Oncology, Inc. | P — Open-market purchase | 13.5K | $6.64 | $90K |
| 2025-08-12 | KURA | Kura Oncology, Inc. | P — Open-market purchase | 36.5K | $5.85 | $214K |
| 2025-08-06 | RNAM | Avidity Biosciences, Inc. | S — Open-market sale | 17.8K | $45.00 | $800K |
| 2025-08-06 | RNAM | Avidity Biosciences, Inc. | S — Open-market sale | 17.8K | $45.00 | $800K |
| 2025-08-06 | RNAM | Avidity Biosciences, Inc. | S — Open-market sale | 15.0K | $45.00 | $675K |
| 2025-08-06 | RNAM | Avidity Biosciences, Inc. | S — Open-market sale | 15.0K | $45.00 | $675K |
| 2025-08-06 | RNAM | Avidity Biosciences, Inc. | S — Open-market sale | 7.5K | $45.00 | $338K |
| 2025-08-06 | RNAM | Avidity Biosciences, Inc. | M — Option exercise | 7.5K | $12.48 | $94K |
Troy Edward Wilson is the President and CEO of Kura Oncology, Inc., a biopharmaceutical company focused on precision medicines for cancer treatment. He has also held leadership roles at Avidity Biosciences, Inc., contributing to the development of innovative therapies.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 3 open-market purchases ($713K) and 10 open-market sales ($6.16M) across all tracked filings.
Across 3 tracked purchases, WILSON TROY EDWARD averaged +3078.9% avg 30-day return with a 10000% 30-day win rate. InsiderAlpha rates the track record at 5/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live WILSON TROY EDWARD profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.